Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.65 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.63 |
| ▸ | HTR7 | P34969 | 4/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | RAD52 | P43351 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | OXTR | P30559 | 1/20 | 0.58 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 9/20 | 0.57 |
| ▸ | HTR2C | P28335 | 8/20 | 0.57 |
| ▸ | HTR2B | P41595 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764873 | 0.96 | MAPKAPK2 (0.66) | PRMT5MAPKAPK2HTR7CHRM4DRD2 | |
| SCHEMBL764778 | 0.94 | MAPKAPK2 (0.70) | PRMT5MAPKAPK2HTR7RAD52MAPT | |
| SCHEMBL764714 | 0.91 | MAPKAPK2 (0.72) | PRMT5MAPKAPK2HTR7DRD2HTR2A | |
| SCHEMBL765058 | 0.88 | HTR7 (0.72) | MAPKAPK2HTR7CHRM4DRD2MAPT | |
| SCHEMBL764682 | 0.88 | MAPKAPK2 (0.60) | PRMT5MAPKAPK2HTR7RAD52MAPT | |
| SCHEMBL764996 | 0.88 | HTR2A (0.72) | PRMT5MAPKAPK2HTR2AHTR2CHTR2B | |
| SCHEMBL764888 | 0.86 | HTR2B (0.72) | MAPKAPK2HTR7CHRM4DRD2MAPT | |
| SCHEMBL763826 | 0.82 | MAPKAPK2 (0.63) | PRMT5MAPKAPK2HTR7CHRM4DRD2 | |
| SCHEMBL30274482 | 0.82 | HTR2B (0.63) | MAPKAPK2HTR7MAPTHTR2AHTR2C | |
| SCHEMBL8403033 | 0.81 | MAPKAPK2 (0.62) | PRMT5MAPKAPK2HTR7HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8367694-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367694-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-1737461-B1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| EP-2431369-A2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC Therapeutics, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20090209521-A9 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2008127714-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127715-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064683-A1 | Inhibition of VEGF Translation | EIF4E, EIF4EBP1, VEGFA | PRMT5 434/4885MAPKAPK2 1630/4885HTR7 3313/4885 |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | PRMT5 173/4885MAPKAPK2 2808/4885HTR7 1737/4885 |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | PRMT5 95/4885MAPKAPK2 3072/4885HTR7 1701/4885 |
| US-20090209521-A9 | Inhibition of VEGF Translation | EIF4E, EIF4EBP1, VEGFA | PRMT5 434/4885MAPKAPK2 1630/4885HTR7 3313/4885 |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | EIF2AK2, POLRMT, POLM | PRMT5 2709/4885MAPKAPK2 2812/4885HTR7 4338/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | PRMT5 655/4885MAPKAPK2 1807/4885HTR7 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.